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Novel psychoactive substances (NPS) are popular “club/party” drugs that first attracted
attention in the UK in 2009 and remained legal until the 2016 Psychoactive Substances
Act criminalized their distribution. Unlike “traditional” illicit drugs, very little is known
about the influence of their analogs on neuropsychological functioning. We characterized
the cognitive and emotional profile of NPS/polydrug users using the Cambridge
Neuropsychological Test Automated Battery (CANTAB) and EMOTICOM test battery
in adult male (aged 20–49 years) recreational users without psychiatric comorbidities
(n = 27; “psychonauts”), service users attending a UK specialist “Club Drug” Clinic for
problematic use (n = 20) and healthy control volunteers without significant drug-taking
histories (n = 35). Tasks were selected to distinguish “hot” cognitive processes that are
highly influenced by emotion from “cold” cognitive processes that are largely independent
of emotional influence. Both user groups reported significantly higher sensation-seeking
traits compared with non-users. Recreational NPS users demonstrated more risk-
taking behavior compared with controls and treatment-seeking NPS users showed
poorer learning, episodic memory and response inhibition compared with the other
two groups. These effects persisted, when controlling for age, intelligence, alcohol
and cannabis use severity, nicotine dependence, trait anxiety, depression, childhood
adversity, impulsivity, and sensation seeking. Overall, recreational NPS users showed
elevated “hot” (emotion-laden) cognition in the absence of “cold” (non-emotional)
cognitive deficits, whereas “cold” cognitive dysfunction was pronounced in individuals
seeking treatment for problematic NPS use. High trait impulsivity and poor self-control
may confer additional risk to NPS/polydrug use severity and separate those seeking
treatment from those using NPS recreationally.
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INTRODUCTION
Novel psychoactive substances (NPS; formerly called “legal
highs”) are compounds that are designed to mimic the effects
of “traditional” illicit drugs such as amphetamines, ecstasy
and cannabis (1–3). Here the term novel does not refer to
newly invented substances, but rather to those that are newly
synthetized (or available) (4). Other terms that have been used to
describe these substances include “club drugs,” “designer drugs,”
“party drugs,” “internet drugs,” and “research chemicals.” Recent
drug monitoring reports have indicated an increase in the use,
availability and harmful effects of NPS (5, 6), with the total
number of new drugs being monitored globally reaching 892 in
2018 (7).
NPS can be broadly grouped into four main categories
based on their mechanisms of action: stimulants (e.g.,
cathinones, piperazines, and phenethylamines), depressants
(benzodiazepines, e.g., diclazepam and opioids, e.g., novel
fentanyls), hallucinogens (dissociatives, e.g., methoxetamine
and hallucinogens, e.g., 2C-series) and synthetic cannabinoids
(e.g., CB1 and CB2 receptor agonists) (1, 8–11). While most
established illicit drugs have distinct effects, many NPS are
part of groups of similar substances with relatively similar
effects (e.g., cathinones) or dissimilar substances with similar
effects (e.g., synthetic cannabinoids) (12). The pharmacological
profiles of NPS within the same classification can also resemble
different established substances (e.g., cocaine/MDMA- and
methamphetamine-like cathinones) (13). NPS are frequently
recognized as one component of polysubstance use, which is
generally added to, rather than replace, existing drug-taking
repertoires (14, 15). NPS users are generally male (16–18) and
from urban areas, with subgroups including adolescents and
young adults (15–25 years), students and clubbers (19, 20). Gay
and bisexual men are also often amongst the “early adopters” of
new “club drug” trends (21). So-called “psychonauts” (sometimes
called “cyber-psychonauts” or “e-psychonauts”) are an additional
key group. They are well-educated and highly informed NPS
users, who possess detailed pharmacological/pharmaceutical
knowledge about the drugs they take (22). “Psychonauts” are
known to experiment with combinations of hallucinogenic
drugs, often sharing detailed records of their experiences
online (23–25). Although some NPS users are driven by drug-
specific effects (e.g., hallucinogens for self-exploration/spiritual
attainment and stimulants for social enhancement), online
surveys have identified curiosity, pleasure, and enjoyment as the
main motivations for use (16, 26, 27). Ease of access, affordability
and low detectability in drug screening tests are also important
motivators (17, 28).
An increasing number of people receive treatment for
NPS-related harms in the UK (29). These include acute
toxicity, risky sexual and drug-sharing behaviors and adverse
psychiatric, cardiovascular, renal and gastrointestinal effects
(18, 30). Cognitive alterations have been well-documented in
substance use disorders and predict treatment outcome (31).
However, unlike “traditional” illicit drugs, very little is known
about the influence of their novel analogs on neuropsychological
functioning. We aimed to redress this by comparing cognitive
and emotional functions in recreational NPS users without
psychiatric comorbidities (n = 27; “psychonauts”), service-users
attending a UK specialist “Club Drug” Clinic for problematic
use (n = 20) and healthy control volunteers without significant
drug-taking histories (n = 35). On the basis of previous research
showing high risk-related behavior in NPS users (32), we
hypothesized that our NPS groups would show elevated “hot”
(emotion-laden) cognition compared with controls. We further
hypothesized that our treatment-seeking NPS group would show
broad “cold” (non-emotional) cognitive deficits compared with
the other two groups, reflecting greater substance use severity
and/or comorbid psychopathology typical of NPS/polydrug users
in treatment (33, 34). Lastly, we explored reasons for NPS/club
drug use, hypothesizing that consistent with previous studies
(16, 26, 27), curiosity and experience seeking would be the main
motivations in both user groups.
MATERIALS AND METHODS
Participants
Treatment-seeking NPS users were referred from the NHS
Central North West London (CNWL) “Club Drug” Clinic
(www.clubdrugclinic.cnwl.nhs.uk). Recreational NPS users
(psychonauts) were recruited from the community via
posted flyers, online (e.g., advertisement on NPS forums),
psychedelic/psychonauts societies and word-of-mouth. We
were primarily interested in individuals who were positive
about their lifestyle and experimented with NPS for a novel or
unusual experience. Healthy control volunteers were recruited
via mailing lists, posted flyers and from the Behavioral and
Clinical Neuroscience Institute research volunteer database. All
participants gave written informed consent.
Inclusion criteria were male, English-speakers, between 18
and 49 years of age. Participants in the recreational group
reported NPS use at least twice a month in the past 3 months.
Participants in the treatment-seeking group were currently
receiving health care services for problematic NPS use as defined
by ICD-10 criteria for harmful or dependent use (35). Exclusion
criteria for the recreational NPS group were current psychiatric
disorder; current harmful alcohol use as defined by a score
≥15 (36, 37) on the Alcohol Use Disorders Test [AUDIT;
(38)]; current harmful cannabis use as defined by a score ≥13
on the Cannabis use Disorders Test-Revised [CUDIT-R; (39)];
and current psychoactive medication. Exclusion criteria for the
treatment-seeking NPS group were current or past acute or
drug-induced psychosis; current antipsychotic medication; and
current infectious disease. Exclusion criteria for healthy controls
were current or past neurological or psychiatric conditions;
current or past substance use (excluding low-risk alcohol use as
defined by an AUDIT score <8; <10x lifetime cannabis use was
permitted, but only if not used in the past 6 months); and current
psychoactive medication. Additional exclusion criteria for all
participants were past serious traumatic head injury and severe
physical impairments affecting eyesight or motor performance.
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Measures
Substance Use
Alcohol and cannabis use severity were measured using
the AUDIT (38) and CUDIT-R (39). Nicotine dependence
was measured using the Fagerström Test for Nicotine
Dependence [FTND; (40)], which assesses the quantity of
cigarette consumption, the compulsion to use and dependence.
Reasons for NPS/club drug use were explored in the two user
groups by asking them to endorse up to 34 fixed reasons (e.g.,
pleasure/enjoyment; facilitation of social situations; stress relief)
using a semi-structured interview.
Psychopathology
Current symptoms of attention deficit/hyperactivity disorder
(ADHD) were assessed with the Adult ADHD Self-Report Scale
[ASRS; (41)]. Anxiety and depression were assessed with the
Spielberger Trait Anxiety Inventory [STAI; (42)] and Beck
Depression Inventory [BDI-II; (43)]. Childhood adversity was
assessed with the Childhood Trauma Questionnaire [CTQ; (44)].
Impulsivity and Sensation Seeking
Impulsivity was assessed with the Barratt Impulsiveness Scale
[BIS-11; (45)]. Sensation seeking, including thrill and adventure
seeking (e.g., participation in highly stimulating physical
activities), disinhibition (e.g., varied sexual and/or drug-seeking
behaviors), experience seeking (e.g., pursuit of novel and/or
unconventional experiences), and boredom susceptibility (e.g.,
aversion to repetition and/or prediction) were assessed with the
Sensation Seeking Scale [SSS-V; (46)].
Neuropsychological Functioning
Premorbid IQ was estimated using the National Adult
Reading Test [NART; (47)]. Standardized neuropsychological
tasks were selected from the reliable and well-validated
EMOTICOM neuropsychological test battery (48) and
Cambridge Neuropsychological Test Automated Battery
(CANTAB; www.cambridgecognition.com).
“Hot” Cognition (Impulsivity and Risk-Taking
Behavior)
The Discounting task (DT) (48) assesses temporal discounting
across five levels of delay (0, 30, 90, 180, and 365 days) and
probability (25, 50, 75, 90, and 100%). Participants must choose
between a standard fixed amount (always £20) associated with
a particular delay or probability and an alternative amount
available immediately. Indifference points are calculated for each
length of delay and degree of uncertainty. These refer to the
amount of immediately available money that the participant
considered to be equivalent to the delayed or uncertain
reward. Area under the curve (AUC) was calculated using the
following formula:
AUC (for delay discounting) = [(2-0)∗((indifference
point at 0 days + indifference point at 2 days)/2)] +
[(30-2)∗((indifference point at 2 days + indifference
point at 30 days)/2) + [(180-30)∗((indifference point
at 3 days + indifference point at 180 days)/2)] +
[(365−180)∗((indifference point at 180 days+ indifference
point at 365)/2)].
A smaller AUC indicates more severe discounting of the delayed
reward (i.e., greater impulsivity). A similar formula was used for
probability discounting, with a smaller AUC indicating greater
risk aversion.
The Cambridge Gambling task (CGT) (48) assesses risk-
taking behavior outside of a learning context. Participants are
shown a roulette wheel with two different proportions of colors.
Participants are asked to place a monetary bet on the outcome
they expect (i.e., which color the wheel pointer will land on when
spun). There are five different wheel proportions, ranging from
very certain to very uncertain. In the win (reward) condition,
participants either double (if they win) or retain (if they lose)
their bet. In the loss condition, participants lose their bet if
they make the wrong selection. Risk adjustment quantifies bet
calibration across ratios (calculated for the reward and loss
conditions separately) using the following formula (a higher
score is preferable):
Risk adjustment= (2∗bet at 90%)+ (1∗bet at 80%)+ (0∗bet at
70%) – (1∗bet at 60%) – (2∗bet at 50%)/Average bet.
“Cold” Cognition (Memory, Attention, and Executive
Functions)
Learning and episodic memory were assessed using the Paired
Associates Learning (PAL) task (49). Boxes are displayed on a
screen and opened in a randomized order, some of which contain
a pattern. The participant must touch the box where they think
the pattern was originally located. If an error is made, then the
patterns are presented again. Outcomemeasures include the total
number of errors made, the total number of trials required to
locate all of the patterns correctly and first trial memory score
(i.e., the number of patterns correctly located after the first trial
summed across the number of stages completed).
Attention and executive functions were measured using the
Rapid Visual Information Processing (RVP) task, the Spatial
Working Memory (SWM) task, and the Stop-Signal Task (SST).
The RVP task assesses sustained visual attention (50). Single
digits appear in the center of the screen at a rate of 100 digits per
minute. Participantsmust detect a series of three targets (e.g., 3-5-
7) by pressing a button as quickly as possible. Sensitivity detecting
the target sequence regardless of response tendency (A’) is the
main outcome measure.
The SWM task assesses ability to retain spatial information
and manipulate remembered items in working memory (51).
Using a process of elimination, participants are instructed to find
a yellow token in boxes appearing on the screen. The position of
the boxes changes and the number of boxes increases for each
trial. Outcome measures include between errors (revisiting a box
in which a token has previously been found) and strategy (a
predetermined sequence by beginning with a specific box and
then, once a token has been found, returning to that box to start
a new search sequence).
The SST measures response inhibition (52). Participants first
respond to an arrow stimulus by selecting a button depending
on the direction in which it points (counterbalanced and
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intermixed). Participants are later asked to withhold making
a response if a 300Hz, 100ms audio tone (i.e., stop-signal) is
present (25% of the trials). The task uses a staircase design to
adapt to the participant’s performance, allowing for a 50% success
rate for inhibition. Participants were instructed to respond as
quickly and accurately as possible. The task includes 16 practice
trials, 240 “Go” trials and 80 “stop” trials. Outcome measures
include direction errors, proportion of successful stops, reaction
time on “Go” trials and stop-signal reaction time (SSRT, i.e., the
time taken to abort an initiated action in the presence of a stop-
signal). SSRT was only estimated for participants successfully
inhibiting 25–75% of their responses (53).
Procedure
This study receivedUniversity of Cambridge Psychology research
ethics approval (Pre.2015.51; Pre.2020.087) and East of England
Cambridge Central research ethics committee approval (ref
17/EE/0453). Volunteers in the recreational NPS and healthy
control groups were screened for study criteria by telephone
and via semi-structured interview using the Mini-International
Neuropsychiatric Inventory [MINI; (54)]. Volunteers in the
treatment-seeking NPS user group were referred by keyworkers
from the CNWL Club Drug Clinic. Participants of each group
were recruited in parallel. Invited participants attended a single
3-h session at the Behavioral and Clinical Neuroscience Institute,
their home or the clinic. Participants were asked to abstain
from alcohol consumption 24 h prior to the experiment and
nicotine from the morning of the session. On arrival participants
completed basic demographic and substance use measures.
Neuropsychological tests were then administered in a fixed order.
Participants then completed questionnaire measures, followed by
a semi-structured interview to assess reasons for drug/club drug
use. Volunteers were offered breaks as necessary (smoking was
permitted after tests of neuropsychological functioning) and paid
for their participation.
Statistical Analyses
Analyses were conducted using SPSS 27.0. Demographic,
substance use and trait measures were analyzed by group
using one-way analysis of variance (ANOVA) or chi-square
tests as appropriate. Three-group comparisons were made
for each neuropsychological test measure using univariate
analysis of covariance (ANCOVA), covarying for age, intelligence
(IQ; NART), alcohol and cannabis use severity (AUDIT,
CUDIT-R), nicotine dependence (FTND), trait anxiety (STAI),
depression (BDI-II), childhood adversity (CTQ), impulsivity
(BIS-11), and sensation seeking (SSS-V). These measures
were selected to better isolate any observed effects to the
influence of NPS/comorbid polydrug use. The Benjamini-
Hochberg procedure was applied at q < 0.15 to control for
false discovery for each neuropsychological test battery; all
significant p-values remained (two-sided). For models reaching
significance, planned pairwise comparisons of covariate-adjusted
means were followed-up post-hoc. Correlational analyses between




Substance Use, and Personality Trait
Measures
The three groups were well-matched in age, IQ and years
in education. However, fewer of those seeking treatment
were currently employed or studying (Table 1). Participants
in the treatment-seeking NPS group met ICD-10 criteria (35)
for mental and behavioral disorder due to harmful cocaine
(5%), cannabis (10%), and hallucinogen use (5%); mental
and behavioral disorder due to dependent sedative/hypnotic
(15%), volatile solvent (10%), and stimulant (35%) use. Harmful
ketamine (20%), alcohol (5%), cocaine (5%), benzodiazepine
(5%), and other psychoactive substance (5%) use were also
reported. Psychiatric diagnoses in the treatment-seeking NPS
group were generalized anxiety disorder (30%), depression
(30%), borderline personality disorder (10%), and panic disorder
(5%). Current prescribed medications were mirtazapine (15%),
propranolol (10%), diazepam (10%), fluoxetine (5%), sertraline
(5%), citalopram (5%), alprazolam (5%), codeine (5%), and
naltrexone (5%).Medications that were taken, but not prescribed,
were diazepam (20%) and propranolol (5%).
All participants in the NPS groups reported using
combinations of novel psychoactive and illicit substances
(Table 1). Age of first NPS use did not significantly differ
between the two user groups (p = 0.62). Self-reported severity of
alcohol, cannabis and nicotine use were significantly higher in
the treatment-seeking NPS group compared with the other two
groups (all p’s < 0.007). Cannabis (p < 0.001), but not alcohol (p
= 0.19) or nicotine (p = 0.10) use severity significantly differed
between the recreational NPS and control groups. Nicotine use
was generally low in all three groups. Drug-sharing and injecting
behaviors were significantly higher in the treatment-seeking NPS
group (p’s ≤ 0.04).
As expected, the three groups significantly differed in trait
anxiety, depression, ADHD symptoms, childhood adversity,
impulsivity, and sensation-seeking traits (Table 1). Post-hoc
comparisons showed that the treatment-seeking NPS group
scored significantly higher on all trait measures compared
with both the recreational NPS and control groups (all p’s <
0.006), except for sensation seeking (total score), which did
not significantly differ from the recreational NPS group [mean
difference = −1.14, p = 0.52, 95%CI (−4.69, 2.41)]. Sensation
seeking was the only trait measure that was significantly higher
in the recreational NPS group compared with the control group
[mean difference = 7.16, p < 0.001, 95%CI (4.09, 10.23)].
On sensation seeking subscales, the two NPS groups did not
significantly differ (all p’s > 0.37). However, the NPS groups
showed significantly more disinhibition, experience seeking and
boredom compared with the control group (all p’s ≤ 0.02).
“Hot” Cognition
Delay and probability discounting (DT) did not significantly
differ between the three groups (Table 2). However, the
recreational NPS group showed significantly worse risk
adjustment (i.e., more risk-taking behavior; CGT) compared
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TABLE 1 | Demographic information, psychopathology, trait measures, substance use severity (means and standard deviations), and percentages of novel psychoactive








Statistic, p-value, effect size
Demographics
Age (years) 26.43 (6.84) 25.11 (3.90) 28.95 (5.11) F (2,79) = 2.73, p = 0.07, η
2
= 0.07
IQ (NART) 116.17 (6.20) 117.00 (6.79) 114.10 (7.55) F (2,79) = 1.10, p = 0.34, η
2
= 0.03
Education (years) 15.20 (2.18) 14.78 (2.03) 14.15 (1.81) F (2,79) = 1.68, p = 0.19, η
2
= 0.04
In work or education (%) 100% 96% 40% X2 = 38.80, p < 0.001, V = 0.69
Psychopathology
Trait Anxiety (STAI-T) 38.86 (10.78) 39.32 (10.69) 54.00 (11.11) F(2,77) = 14.29, p < 0.001, η
2
= 0.27
Depression (BDI-II) 6.69 (7.67) 9.20 (8.65) 22.37 (13.35) F(2,76) = 17.27, p < 0.001, η
2
= 0.31
ADHD symptoms (ARSC) 1.97 (1.60) 1.92 (1.61) 4.05 (1.39) F(2,76) = 13.20, p < 0.001, η
2
= 0.26




Impulsivity (BIS-11) 60.11 (11.15) 64.52 (9.39) 73.15 (8.04) F(2,77) = 11.01, p < 0.001, η
2
= 0.22
Sensation seeking (SSS-V total) 19.56 (6.95) 26.72 (4.67) 25.58 (5.03) F(2,75) = 12.65, p < 0.001, η
2
= 0.25
Thrill/adventure seeking 6.24 (2.19) 6.88 (2.71) 6.63 (2.52) F (2,75) = 0.41, p = 0.67, η
2
= 0.01
Disinhibition 4.26 (2.57) 7.04 (1.67) 6.95 (2.04) F(2,75) = 14.94, p < 0.001, η
2
= 0.29
Experience seeking 6.03 (1.75) 8.24 (1.69) 7.79 (1.58) F(2,75) = 14.00, p < 0.001, η
2
= 0.27




Age of first NPS use (years) 20.33 (3.22) 21.00 (5.86) t(45) = 0.50, p = 0.62, η
2
= 0.01
Alcohol use (AUDIT) 3.91 (2.44) 5.70 (3.45) 11.40 (9.41) F(2,79) = 13.13, p < 0.001, η
2
= 0.25
Cannabis use (CUDIT-R) 0.00 (0.00) 4.19 (3.54) 8.20 (7.34) F(2,79) = 25.82, p < 0.001, η
2
= 0.40
Nicotine use (FTND) 0.37 (1.01) 0.37 (1.26) 1.60 (2.19) F(2,79) = 5.27, p = 0.01, η
2
= 0.19
Drug-sharing behavior (%) 19% 53% X2 = 5.91, p = 0.02, V = 0.36
Drug-injecting behavior (%) 11% 37% X2 = 4.34, p = 0.04, V = 0.31
Novel psychoactive substance use (%
past 90 days)
Ketamine 5.7% 60%
Nitrous oxide 44.4% 10%
Mephedrone 7.4% 30%
2C (2CB, 2CE) 29.6% 10%
1-propionyl-lysergic acid diethylamide 25.9% 0%
Synthetic cannabinoids 3.7% 20%
Gamma Hydroxybutyrate 0% 15%
Methoxetamine 0% 15%
Alkyl nitrites (poppers) 14.8% 0%
Ethylphenidate 0% 10%
Salvia divinorum 0% 10%
25I-NBOMe 0% 10%
Kratom (Mitragyna specios) 7.4% 0%
Methylone 0% 5%
Kratom 0% 5%
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Statistic, p-value, effect size









Crack cocaine 0% 10%
Heroin 0% 10%
Lysergic acid diethylamide 3.7% 5%
NART, National Adult Reading Test; AUDIT, Alcohol Use Disorders Identification Test; CUDIT-R, Cannabis Use Disorder Identification Test-Revised; FTND, Fagerström Test of Nicotine
Dependence; BDI-II, Beck Depression Inventory; STAI, Spielberger Trait Anxiety Inventory; ARSC, Adult ADHD Self-Report Scale; CTQ, Childhood Trauma Questionnaire, BIS-11, Barratt
Impulsiveness Scale; SSS-V, Sensation Seeking Scale. Bold indicates p < 0.05.
with the control group [mean difference = −0.84, p = 0.01,
95%CI (−1.47, −0.21)]. Risk adjustment in the recreational NPS
group did not significantly differ from the treatment seeking-
NPS group [mean difference = −0.25, p = 0.52, 95%CI (−1.02,
0.52)]. Riskier behavior by the recreational NPS group compared
with controls was observed in the loss condition only. Across
the entire sample, higher impulsivity was associated with riskier
behavior in the win condition, r = −0.25, p = 0.03 (Figure 1).
Sensation seeking (total score) was not significantly associated
with riskier behavior, r =−0.17, p= 0.15.
“Cold” Cognition
Memory performance significantly differed between the three
groups (Table 2). The treatment-seeking NPS group showed
significantly poorer learning and episodic memory compared
with the other two groups [PAL errors: treatment vs. recreational
mean difference = 49.84, p = 0.001, 95%CI (20.98, 78.70);
treatment vs. control mean difference= 66.22, p < 0.001, 95%CI
(30.61, 101.83); PAL trials: treatment vs. recreational mean
difference = 4.18, p = 0.03, 95%CI (0.46, 7.91); treatment vs.
control mean difference = 6.75, p = 0.01, 95%CI (2.16, 11.35)].
Memory performance did not significantly differ between the
recreational NPS and control groups [errors: mean difference =
16.38, p = 0.18, 95%CI (−7.93, 40.70); trials: mean difference =
2.57, p= 0.11, 95%CI (−0.57, 5.71)].
Stop-signal reaction time (SSRT) also significantly differed
between the three groups (Table 2). The treatment-seeking
NPS group showed a significantly longer stopping response
(i.e., poorer self-control) compared with the other two groups
[treatment vs. recreational mean difference = 34.38, p = 0.04,
95%CI (1.78, 66.97); treatment vs. control mean difference =
59.33, p= 0.01, 95%CI (18.94, 99.73)]. SSRT did not significantly
differ between the recreational NPS and control groups [mean
difference= 24.96, p= 0.08, 95%CI (−2.66, 52.58)]. Three-group
comparisons formeasures of attention (RVP) and spatial working
memory (SWM) were not significant (p’s > 0.17) and therefore
not followed-up.
Reasons for NPS/Club Drug Use
In the recreational NPS group, the top three reasons for use
were (1) “out of curiosity to see what effects they might have
on me” (74%); and (2 and 3 [tied]) “to feel elated or euphoric”
and “to get an unusual experience, or experience a different state
of mind” (70%). In the treatment-seeking NPS group, the top
three reasons for use were: (1) “to get an unusual experience, or
experience a different state of mind” (90%); (2) “to get really stoned
or intoxicated” (70%); and (3) “out of curiosity to see what effects
they might have on me” (60%). Additional reasons for NPS/club
drug use are presented in Figure 2.
DISCUSSION
We conducted, to our knowledge, the first quantitative study
investigating the relationship between NPS/polydrug use and
neuropsychological functioning. Carefully controlling for an
array of key demographic, substance-related and trait measures
likely to impact neuropsychological functioning, we firstly
found that recreational NPS users showed significantly worse
risk adjustment compared with controls. We secondly found
that treatment-seeking NPS users showed significantly poorer
learning, episodic memory, and response inhibition compared
with the other two groups. Together, these findings indicate
that risk-taking behavior was higher in recreational NPS users,
whereas group differences in episodic memory and inhibitory
control processes were driven by those seeking treatment,
suggesting possible dissociable effects of NPS/polydrug use
severity on “hot” and “cold” cognitive processes.
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Delay (area under the curve) 4631.54 (2181.80) 4641.78 (2010.98) 3738.42 (1805.34) F (2,64) = 1.13, p = 0.33, η
2
= 0.03




New Cambridge Gamble Task
Risk adjustment (reward) 2.54 (0.68) 2.00 (0.90) 1.79 (0.98) F (2,64) = 2.05, p = 0.14, η
2
= 0.06






Total errors 12.88 (8.89) 23.08 (19.46) 64.58 (61.57) F(2,65) = 7.46, p = 0.001, η
2
= 0.19
Total trials 9.12 (2.28) 12.20 (5.23) 17.37 (6.10) F(2,65) = 4.31, p = 0.02, η
2
= 0.12




Rapid Visual Information Processing





Between errors 14.21 (12.08) 22.96 (13.45) 32.11 (24.13) F (2,64) = 1.78, p = 0.18, η
2
= 0.05




Direction errors 1.64 (2.22) 2.29 (3.54) 1.76 (1.99) F (2,61) = 1.39, p = 0.26, η
2
= 0.04
Proportion of successful stops 0.49 (0.10) 0.48 (0.10) 0.52 (0.07) F (2,61) = 0.73, p = 0.49, η
2
= 0.02
Reaction time on Go trials (median) 461.03 (174.39) 476.33 (145.35) 517.38 (141.66) F (2,61) = 0.23, p = 0.77, η
2
= 0.01
Stop-signal reaction time (SSRT) 163.65 (39.94) 162.91 (32.50) 194.59 (51.66) F(2,61) = 4.32, p = 0.02, η
2
= 0.12
Analyses are controlling for age, IQ (NART), alcohol and cannabis use severity (AUDIT, CUDIT), nicotine dependence (FTND), trait anxiety (STAI-Trait), depression (BDI-II), childhood
adversity (CTQ), impulsivity (BIS-11), and sensation seeking (SSS-V). Bold indicates p < 0.05.
Elevated Risk-Taking Behavior in
Psychonauts
Recreational NPS users showed riskier behavior on our gambling
task (CGT), specifically toward a potential negative outcome.
NPS use is associated with risky behaviors (30), which may
reflect alterations in “hot” decision-making related to searching
for excitement, taking risks for the sake of new experiences
and/or lower perception of drug-related risks (32, 55). More
risk taking in the loss condition suggests that recreational
NPS users may be less sensitive to negative outcomes or more
optimistic about their decision-making. They may also exhibit
“loss-chasing” behavior whereby betting becomes more amplified
in an effort to recover prior losses (56). It is important to
note that sensation seeking and impulsivity are two personality
traits that are prominent in substance-dependent individuals
(55, 57). Whereas, both of our NPS user groups reported high
sensation seeking, those seeking treatment were additionally
characterized by high trait impulsivity. We further found that
across our sample, higher levels of trait impulsivity (and not
sensation seeking) were associated with more risk taking toward
potential reward (see Figure 1). The lack of correlation with
sensation seeking is likely due to its dimensions not explicitly
relating to non-social rewards, including monetary earnings
used in this task. The significant association between trait
impulsivity and risk-taking in the win condition indicates an
approach response for rewarding stimuli. This likely reflects rash
impulsiveness, a dimension of impulsivity involving difficulty
inhibiting one’s behavior when engaging in rewarding activities
(58). Rash impulsiveness is thus a key personality trait that
promotes risk-taking behavior through activation of unplanned
and immediate decision-making.
“Cold” Cognitive Deficits in
Treatment-Seeking NPS Users
In contrast to elevated “hot” cognition, we did not find impaired
“cold” cognition in our recreational NPS group relative to non-
users, which likely reflects their overall good general health.
Indeed, the recreational NPS users in our sample reportedmainly
using novel hallucinogens, the class of NPS associated with the
lowest harm profile (1). “Psychonauts” are well-educated and
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FIGURE 1 | Association between trait impulsivity (BIS-11) and risk adjustment (Cambridge Gamble task, win condition).
FIGURE 2 | Endorsed reasons for NPS/club drug use by (%) group.
knowledgeable about the NPS they use, with an almost academic-
like interest in thinking about hallucinogenic drug experiences
(59, 60). This aligns with highly intelligent and socially integrated
recreational users who incorporate regular drug taking into their
lives without transitioning to dependence (61), suggesting shared
resilience factors (62) such as demographic (e.g., intelligence)
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and/or personality features (e.g., low impulsiveness). Our data
provide the first behavioral evidence that recreational NPS users
demonstrate higher risk-taking in the absence of core “cold”
cognitive deficits, which may protect against more adverse
consequences of chronic NPS/polydrug use.
A more severe profile of “cold” cognitive dysfunction was
observed in our treatment-seeking NPS group compared with
both the recreational NPS and control groups. Specifically,
they made more errors and needed more trials to learn the
correct associations between a stimulus and a spatial location
on our memory task (PAL). Impaired episodic memory is highly
prevalent in male substance users (63). Difficulties forming
paired associations strongly relate to structural changes in the
hippocampal formation, a key region that is amongst the first to
be altered by the course of drug addiction (64). Our treatment-
seeking NPS group further showed difficulty with self-control.
Inhibitory control is a core executive function subserved by
cortical and subcortical structures including the inferior frontal
gyrus (65). Similar to previous studies in stimulant drug users, we
found a slower stopping response (SSRT) in the presence of intact
psychomotor speed (“Go” reaction time) (66) in the treatment-
seeking NPS users. Stopping response in the recreational NPS
users was comparable with controls, suggesting good self-
control in both groups. Of strong clinical interest, the significant
difference in SSRT performance between the NPS user groups
suggests that the inability to stop a prepotent response once
initiated separated those seeking treatment from those using NPS
recreationally. Impulsivity and lack of self-control (SSRT) are
vulnerability factors that may predate drug taking, rendering
some individuals more susceptible to developing problematic use
(67). This is in stark contrast with sensation-seeking traits, which
may contribute to the initiation of NPS use, but not escalation
to dependence.
Reasons for NPS/Club Drug Use
Reasons for NPS/club drug use corresponded with those
reported by previous studies (16, 26, 27), and mainly reflected
curiosity, experience seeking and the desire to get high and/or
intoxicated. However, some distinct motivational patterns of
NPS use emerged by group. Similar to hallucinogen drug users
(68), inducing feelings of euphoria (i.e., pleasure/happiness)
was specific to recreational NPS users. In those seeking
treatment, feeling depressed/down and drug craving were
reported, indicating some degree of negatively reinforced NPS
use. Coping with negative emotions is one motivational pathway
that could be targeted by treatment interventions for problematic
NPS use. Substance enhancement (i.e., intensifying combined
effects) was also more prevalent in our treatment-seeking NPS
group, which can facilitate increased polydrug use associated with
negative emotional states.
It is worth noting that as expected, psychopathology was high
in our treatment-seeking NPS group, with over half the sample
(55%) meeting criteria for at least one psychiatric diagnosis.
Case studies have reported that NPS use can induce psychiatric
symptoms in individuals with no prior mental health difficulties
and exacerbate symptoms in those with severe mental illnesses
(33). Although we were unable to determine if psychiatric
symptoms predate or emerge as a consequence of NPS use (or
some other contributing factor, such as childhood adversity), the
high prevalence of comorbid psychopathology is consistent with
more clinical features being present in individuals with higher
NPS/polydrug use severity (34).
Clinical Implications
Our study has clinical implications. Most NPS users are new to
drug treatment services (19, 69), where healthcare professionals
report feeling less confident managing cases of novel compared
with established substances (70). As such, “club drug” clinics
require specialist staff and training to better understand the
complexity of NPS types, the context in which they are used
and the most appropriate treatment strategies. We suggest that
problematic NPS use could be screened through new tools that
take into account the pattern of neuropsychological deficits
observed here. For example, a “clinician-friendly” screening tool
could be developed to detect impaired inhibitory control (or a
more general “cold” cognitive assessment) in treatment-seeking
NPS users. Self-control abilities could then be strengthened by
appropriately matched interventions. In recreational NPS users,
we suggest that risky behaviors (identified by “hot” cognitive
assessment) could be minimized or more safely redirected as key
preventative measures. Rash impulsivity and self-control could
also be profiled in young adults who are at risk of harmful
substance use, particularly if other vulnerability factors (e.g.,
social/environmental) are present.
Limitations
The main limitation of our study is the nominal grouping
of NPS users irrespective of drug class. We acknowledge that
NPS classes may differentially affect physical and psychological
outcomes and that our findings do not capture potential variation
in cognitive performance between subgroups. Larger studies
could also examine differences in cognitive performance in
relation to diagnostic criteria in treatment-seeking samples (e.g.,
harmful vs. dependent use). Another limitation is that we did
not control for treatment effects in our clinic-attending group,
although treatments (e.g., antidepressant medication, cognitive
behavior therapy for substance use disorders) are more likely to
improve, rather than impair, cognitive functions. We also did not
evaluate recency of drug use, which is likely to impact cognitive
performance. Determining what makes recreational NPS users
transition to problematic or dependent use compared with those
who continue using recreationally is also of critical importance.
Our data suggests that sensation seeking traits (predicting the
initiation of NPS use) alongside high trait impulsivity and poor
self-control (predicting the development of compulsive use)
may be a particularly potent combination for differentiating
these groups. Finally, although novel substance use is more
prevalent in men (12, 18), emerging sex/gender differences in the
subjective, clinical and pharmocokinetic responses to NPS pose
an important avenue of new research (71).
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CONCLUSIONS
Overall, we characterized neuropsychological functioning
in NPS/polydrug users, in which two distinct profiles
emerged: elevated “hot” cognition (risk-taking behavior)
in recreational NPS users, and impaired “cold” cognition
(episodic memory, response inhibition) in treatment-seeking
NPS users. Recreational NPS users without significant health
and social problems may seek new or unusual experiences
in the absence of “cold” cognitive deficits. They may also
benefit from protective factors such as better education, more
employment and good control of themselves and their drug use.
In contrast, difficulties with impulsivity and self-control may
confer additional risk to NPS/polydrug use severity in those
seeking treatment. As treatments for substance dependence rely
on sufficient neuropsychological functioning, earlier, targeted
approaches are more likely to be successful in NPS users with
greater use severity, before “rescuing” cognition is the only
option. Synergy between schools/Universities, club/festival
venues and treatment services (i.e., drug, mental, and sexual
health) will be thus be crucial for identifying commonalities
in harmful NPS/polydrug use and dependency. Recognizing
neuropsychological deficits as another component of NPS use
may also help guide preventative and harm reduction strategies,
particularly for higher-risk groups.
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